Erythrocin

Gastroparesis, Erythrasma, Whooping Cough + 60 more

Treatment

68 FDA approvals

20 Active Studies for Erythrocin

What is Erythrocin

Erythromycin

The Generic name of this drug

Treatment Summary

Erythromycin is an antibiotic used to treat various bacterial infections. It was first discovered in 1952 and is part of the macrolide group of antibiotics which includes Azithromycin, Clarithromycin, and Spiramycin. Erythromycin can be administered intravenously, topically, or as eye drops.

Erythrocin Stearate

is the brand name

image of different drug pills on a surface

Erythrocin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Erythrocin Stearate

Erythromycin

1964

261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include Corynebacterium Infections and Urethritis .

Corynebacterium Infections

Urethritis

Staphylococcus (S.) Aureus Infection

urogenital infections during pregnancy

Pertussis

treponema pallidum infection

Diphtheria

Acne Vulgaris

Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin

penicillins

Bacterial Infections

Communicable Diseases

Conjunctivitis

Respiratory Tract Infections

Erythrasma

Postoperative Infections

Listeriosis

Corynebacterium minutissimum infection

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Pneumonia, Mycoplasma

Whooping Cough

Bordetella Pertussis Infection

uncomplicated endocervical infection

Staphylococcal Skin Infections

Communicable Diseases

Acne Vulgaris

Used to treat Acne Vulgaris in combination with Tretinoin

pustular lesions

Used to treat pustular lesions in combination with Avobenzone

Communicable Diseases

Bacterial Infections

Whooping Cough

Pneumonia

Listeria infection

Listeria monocytogenes infection

Acute Otitis Media caused by Haemophilus Influenzae

Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole

inflammatory papular lesions

Used to treat inflammatory papular lesions in combination with Avobenzone

Amebiasis

Common Cold

Rheumatic Fever

prophylaxis of Postoperative Infections

Communicable Diseases

prophylaxis of Rheumatic fever

Ureaplasma urethritis

penicillins

Upper Respiratory Tract Infection

Streptococcus Pneumoniae Infections

Streptococcus pyogenes

Staphylococcal Skin Infections

Urethritis

Urinary Tract Infection (UTI)

Legionella pneumophila

Primary Syphilis

Lower Respiratory Tract Infection (LRTI)

Intestinal amebiasis caused by entamoeba histolytica

Skin and skin structure infections

Corynebacterium Infections

diphtheria antitoxin

Bronchitis

Haemophilus Influenzae Infections

Used to treat Haemophilus Influenzae Infections in combination with null

Urethritis

Ureaplasma urealyticum

skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes

Whooping Cough

Chlamydia Trachomatis

patients with intolerance or contraindications to tetracycline use

Syphilis

First episode of rheumatic fever

Rheumatic Fever

Pneumococcal Infections

Sulfonamides

Effectiveness

How Erythrocin Affects Patients

Macrolides, like erythromycin, treat bacterial infections by preventing the bacteria from making proteins. It is effective against many different types of bacteria, but it is important to check for bacterial resistance before taking this antibiotic. There is a risk of pseudomembranous colitis and liver damage when taking erythromycin, and some strains of Haemophilus influenzae are resistant to erythromycin on its own, but can be treated with erythromycin combined with sulfonamides.

How Erythrocin works in the body

Erythromycin works by preventing bacteria from making proteins which they need to reproduce. It binds to the ribosomes in susceptible bacteria, which are responsible for producing proteins. This stops the bacteria from producing the proteins they need to replicate, thus controlling the bacterial infection. Macrolides like erythromycin have a strong affinity for bacterial ribosomes, which is why they are effective against such a broad range of bacteria.

When to interrupt dosage

The prescribed dosage of Erythrocin is contingent upon the established condition, including Chlamydia Trachomatis, penicillins and Syphilis. The amount of dosage can be found in the following table, depending on the method of delivery (e.g. Granule, for suspension or Tablet, film coated - Oral).

Condition

Dosage

Administration

Amebiasis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Syphilis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Chlamydia Trachomatis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Granuloma Inguinale

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Whooping Cough

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Corynebacterium Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Primary Syphilis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

First episode of rheumatic fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Legionella pneumophila

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

patients with intolerance or contraindications to tetracycline use

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Urethritis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Pneumonia, Mycoplasma

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Acute Otitis Media caused by Haemophilus Influenzae

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Gastroparesis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Listeriosis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Urethritis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Warnings

Erythrocin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Erythromycin may interact with Pulse Frequency

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Erythrocin.

Common Erythrocin Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Erythromycin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Erythromycin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Erythromycin.

Erythrocin Toxicity & Overdose Risk

The lowest toxic dose of erythromycin in rats is 9272mg/kg. Overdosing may cause diarrhea, nausea, stomach pain, and vomiting. If an overdose occurs, the drug should be stopped right away and any unabsorbed drug should be eliminated. Supportive measures should also be taken. Erythromycin cannot be removed from the body by dialysis.

image of a doctor in a lab doing drug, clinical research

Erythrocin Novel Uses: Which Conditions Have a Clinical Trial Featuring Erythrocin?

53 active clinical trials are presently being conducted to determine the potential of Erythrocin in managing Streptococcus pyogenes, Treponema pallidum infection and Rheumatic Fever.

Condition

Clinical Trials

Trial Phases

Acne Vulgaris

3 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Phase 4

Listeriosis

0 Actively Recruiting

Legionella pneumophila

0 Actively Recruiting

Urethritis

0 Actively Recruiting

Ureaplasma urealyticum

0 Actively Recruiting

Acute Otitis Media caused by Haemophilus Influenzae

0 Actively Recruiting

Gastroparesis

14 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Early Phase 1

Acne Vulgaris

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Corynebacterium minutissimum infection

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Urethritis

0 Actively Recruiting

Listeria monocytogenes infection

0 Actively Recruiting

Chlamydia Trachomatis

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

penicillins

1 Actively Recruiting

Phase 3

Primary Syphilis

0 Actively Recruiting

treponema pallidum infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Erythrocin Reviews: What are patients saying about Erythrocin?

5

Patient Review

3/16/2015

Erythrocin for Skin Infection

So far, I've had no negative side effects from this treatment. I'm also taking a probiotic as a preventative measure, since I know that being on an antibiotic for 30 days can sometimes cause irritation.

5

Patient Review

3/2/2017

Erythrocin for Skin Infection

I experienced no negative side effects from this medication, only some light-headedness which went away after a short while. My skin also started to clear up after just a few days. I made sure to take probiotics as well so that I wouldn't get a yeast infection.

5

Patient Review

9/28/2021

Erythrocin for Skin Infection due to Staphylococcus Aureus Bacteria

Erythromycin is a great substitute for those who are allergic to penicillin. It works quickly and effectively against infections with minimal stomach upset.

5

Patient Review

3/2/2017

Erythrocin for Skin Infection

I didn't experience any negative side effects, only some light-headedness occasionally. On the third day of taking this medication, I started to see my skin clearing up. To be safe, I also took probiotics so that I wouldn't get a yeast infection.

5

Patient Review

9/28/2021

Erythrocin for Skin Infection due to Staphylococcus Aureus Bacteria

Erythromycin is a great alternative for people who are allergic to penicillin. It works quickly and efficiently to knock out infections.

5

Patient Review

5/30/2018

Erythrocin for Acute Bacterial Infection of the Sinuses

Erythromycin is a reliable antibiotic that has always worked well for me, much better than the alternatives I've tried.

5

Patient Review

3/16/2015

Erythrocin for Skin Infection

I completed the full 30 days of this treatment and experienced zero negative side effects. I credit this also to taking a probiotic throughout the duration of the antibiotic regimen.

5

Patient Review

5/30/2018

Erythrocin for Acute Bacterial Infection of the Sinuses

Erythromycin is a really effective antibiotic, especially for sinus infections that have spread to the chest. It always works quickly for me, whereas other antibiotics (like Z-packs) haven't been nearly as successful.

4.7

Patient Review

12/8/2016

Erythrocin for Bacterial Pneumonia caused by Streptococcus pneumoniae

I've been using this medication for a little while now and it's going well. In the beginning, I felt a bit strange after taking it but that soon went away.

4.7

Patient Review

11/8/2014

Erythrocin for Strep Throat

I took the medication as directed and had zero issues. I'm not sure what other people are talking about when they say they experienced chest pain and vomiting.

4.7

Patient Review

12/8/2016

Erythrocin for Bacterial Pneumonia caused by Streptococcus pneumoniae

The beginning was tough as I felt hypo and a bit out of it. But by the fourth day, I started feeling better and more like myself again.

4.7

Patient Review

11/8/2014

Erythrocin for Strep Throat

I took the recommended dosage of 250mg four times a day, and I experienced zero negative side effects. I'm not sure what other people are talking about when they say they had problems with chest pains or vomiting--I didn't have any of that.

4.7

Patient Review

1/30/2022

Erythrocin for infection caused by bacteria

I'm currently taking this medication for a possible bacterial infection that might be related to an STI. I was really worried after reading some of the reviews, but so far I haven't had any problems. Some light gas and upper abdominal cramping but nothing too bad.

4.7

Patient Review

1/30/2022

Erythrocin for infection caused by bacteria

I'm using this for a possible bacterial infection that might be related to an STI. I was worried by the negative reviews but so far haven't had any issues. I took 500mg four times throughout the day on the first use, as directed. Some light gas and upper abdominal cramping but not that bad. Guess effect depends on the user.

4.3

Patient Review

12/31/2015

Erythrocin for Pneumonia caused by Bacteria

Quickly lessened my congestion and eased throat pain. I also didn't experience any worrisome side effects, which was great.

4.3

Patient Review

12/31/2015

Erythrocin for Pneumonia caused by Bacteria

Almost immediately after using this product, I noticed a significant reduction in congestion and throat pain. Additionally, I didn't experience any negative side effects, which was great.

3.7

Patient Review

9/6/2017

Erythrocin for Infection caused by the Bacteria Listeria Monocytogenes

Erythromycin is typically effective for me in terms of treating bacterial infections; however, it can be tough on the stomach. I have to make sure to take it with a full meal, otherwise I'll end up feeling extremely famished. All in all, though, it's better than dealing with the infection itself.

3.7

Patient Review

1/6/2020

Erythrocin for infection caused by bacteria

I was prescribed this medication for a tooth infection that eventually required extraction. I experienced significant mental side effects from the drug, including confusion and anxiety. As a result, I stopped taking it before finishing the course of treatment.

3.7

Patient Review

9/6/2017

Erythrocin for Infection caused by the Bacteria Listeria Monocytogenes

Erythromycin always works well for me to clear up infections, but it's hard on my stomach even when I take it with a meal. It makes me feel incredibly Hungry and my tummy growls a lot. However, it does its job overnight usually.

3.7

Patient Review

1/6/2020

Erythrocin for infection caused by bacteria

While this medication did effectively treat my tooth infection and allow me to get the tooth pulled, I stopped taking it because of the mental state it put me in. I was constantly tired, confused, and anxious while on the drug.

2

Patient Review

8/24/2021

Erythrocin for Acne

I experienced diarrhea every day while taking the suggested dosage of 500mg twice a day. After cutting down the dose to 250mg per dose, the frequency of diarrhea decreased; however, I still don't see much change in my acne.

2

Patient Review

8/24/2021

Erythrocin for Acne

I experienced severe diarrhea every day when taking the recommended 500mg dose. Cutting down to 250mg per dose helped, but I didn't see much difference in my acne.

1.3

Patient Review

8/20/2015

Erythrocin for A Severe Skin Infection - Ecthyma

The side effects of this treatment are incredibly unpleasant.

1.3

Patient Review

8/20/2015

Erythrocin for A Severe Skin Infection - Ecthyma

The side effects of this medication are terrible. I experience nausea, vomiting and stomach pain every time I take it.

1

Patient Review

8/29/2022

Erythrocin for Non-Contagious Disease due to Actinomyces Bacteria

I had a terrible reaction to this medication and I would not recommend it to anyone.

1

Patient Review

3/5/2017

Erythrocin for Strep Throat

I had a very negative reaction to this drug. I experienced severe stomach pain, bloating, gas, and seizure-like symptoms. I ended up in the emergency room and it took several hours for me to stabilize. Do not take this drug unless you are absolutely prepared for the possibility of serious side effects.

1

Patient Review

3/5/2017

Erythrocin for Strep Throat

I had an incredibly negative reaction to this drug. It gave me severe stomach pains, bloating, gas, and seizure-like symptoms. I was hospitalized as a result. Please be warned that this drug is not to be taken lightly.

1

Patient Review

8/29/2022

Erythrocin for Non-Contagious Disease due to Actinomyces Bacteria

Do not even think about taking this medication if you are allergic to penicillin. I had a severe reaction that included chest pain, headache, neck pain, cramping, blurred vision, and heart palpitations. And this was only after taking two doses!

1

Patient Review

7/24/2013

Erythrocin for Lyme Disease

Unfortunately, this medication gave me terrible stomach cramps and diarrhea. I also felt very dizzy after taking it.

1

Patient Review

7/24/2013

Erythrocin for Lyme Disease

Unfortunately, this led to stomach cramps and diarrhea for me. Additionally, I felt dizzy while taking it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about erythrocin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Erythrocin for?

"Skin and soft tissue infections.

Erythrocin Tablets contains erythromycin, an active ingredient that belongs to a group of medicines called macrolide antibiotics. These tablets are used to prevent and treat infections such as throat and sinus infections, chest infections (such as bronchitis and pneumonia), and skin and soft tissue infections."

Answered by AI

Is Erythrocin the same as erythromycin?

"The erythrocin stearate film-coated tablet is an antibacterial product that contains the stearate salt of erythromycin. This product is unique because it has a film coating."

Answered by AI

What is Erythrocin 500mg used for?

"Erythrocin 500mg Tablet is an antibiotic used to treat various types of infections. It is effective in most infections of the respiratory tract, ear, nose, throat, lungs, and skin. It prevents the bacteria from proliferating, which helps to resolve the symptoms and cures the infection."

Answered by AI

Clinical Trials for Erythrocin

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Have you considered Erythrocin clinical trials?

We made a collection of clinical trials featuring Erythrocin, we think they might fit your search criteria.
Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA

Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.

Recruiting
Has No Placebo

Children's Community Pediatrics Brentwood (+1 Sites)

Timothy R Shope, MD, MPH

Merck Sharp & Dohme LLC

Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada

The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).

Recruiting
Has No Placebo

Maternity Centre of Hamilton

Laura K Erdman, MD PhD FRCPC

Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA

Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.

Recruiting
Has No Placebo

Benioff Children's Hospital - Oakland (+2 Sites)

Derek J Williams, MD, MPH

Have you considered Erythrocin clinical trials?

We made a collection of clinical trials featuring Erythrocin, we think they might fit your search criteria.
Go to Trials
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA

The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.

Waitlist Available
Has No Placebo

University of Pennsylvania Primary Care Practice

Have you considered Erythrocin clinical trials?

We made a collection of clinical trials featuring Erythrocin, we think they might fit your search criteria.
Go to Trials